Life Sciences Archive » April, 2025

Life Sciences - April, 2025

275 articles

• VSL Probiotic Buyers Win Class Cert. In RICO Case
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Nationwide Says Claim For 'Fat Freezing' Injury Isn't Covered
• Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive
• Del. Judge Won't Let MSN Fight Entresto Orange Book Entry
• Joe Rogan-Backed 'Alpha Brain' False Ad Suit Dropped In NY
• 3rd Circ. Preview: NJ To Defend ICE Contractor Law In May
• Local Gov'ts, Union Seek Block Of COVID Grant Cancellations
• Biotech Co. Throws Flag On NFL Alumni's Bid To Toss Suit
• PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid
• Monthly Merger Review Snapshot
• Mich. AG Says Express Scripts, Prime Fix Pharmacy Rates
• Honeywell, Sourcing Co. End Scuffle Over Soured Supply Deal
• 2nd Frier Levitt Atty Joins Buchanan Ingersoll's Pharmacy Group
• Why Attys Should Get Familiar With Quantum Computing
• Kratom Cos. Get False Ad, Addiction Suit Tossed
• Adapting To Private Practice: From DOJ Enviro To Mid-Law
• Novartis Buying Regulus In Up To $1.7B Kidney Drug Deal
• Gilead Will Pay $202M In DOJ Deal Over Drug Kickbacks
• Omnicare Hit With $136M Jury Verdict For Bilking Feds
• Justices Wary Of Issuing 'Advisory' Ruling In Class Cert. Row
• DC Judge Worries About 340B Rebate Program Without 'Teeth'
• 23andMe Agrees To Privacy Ombudsman In Ch. 11
• Full Fed. Circ. Urged To Undo 'Onerous' Jepson Claim Ruling
• Fed. Circ. Backs TM Denial Of Dark Green Gloves As Generic
• GenBioPro Can Defend FDA Approval In Mifepristone Suit
• Mexico Put On Latest USTR Priority IP Watch List
• Cooley Life Sciences Ace Rejoins Latham In Bay Area
• Opioid MDL Judge Won't Recuse Over Ex Parte Allegations
• High Court Backs HHS In Hospital Pay Formula Dispute
• Chinese Cos. Lose Immunity Fight In 9th Circ. IP Case
• Veolia Settles Flint Water Crisis Claims For $53M
• Gov't Reverses Position On Surgery For Trans Prisoners
• Ziploc 'Microwave Safe' Bags Shed Microplastics, Buyer Says
• Walgreens Opposes Merging 'Non-Drowsy' Labeling Suits
• Sanofi Challenges Jurisdiction In Conn. Zantac Lawsuits
• Ala. Medical Pot Commission Sued Over Patient Registry
• Sullivan & Cromwell-Led Merck To Buy SpringWorks For $3.9B
• HHS Says Cuts Target Excess After Judge Seeks More Info
• SPAC Deals Are Buzzing Again Despite Tariff Turmoil
• Local Gov'ts, Union Sue Over COVID Grant Cancellations
• Judge Says FDA Can Take Ozempic Off Shortage List
• Legal Ethics Considerations For Law Firm Pro Bono Deals
• J&J Unit Sees Claims Trimmed In Engineer's Bias Suit
• Aggressive USPTO Policy Push Suggests 'It's Lutnick's Show'
• Ozempic Maker Settles Infringement Claims With Atlanta Clinic
• Insulet's $452M Trade Secrets Award Reduced To $59.4M
• 11th Circ. Backs FDA In Denial Of Bidi's Vape Application
• Reproductive Health Under Trump So Far, And What's Next
• Playing Football Made Me A Better Lawyer
• Circuit-By-Circuit Guide As Justices Confront Class Cert. Split
• Biz Court Questions What Ties TikTok To NC In Addiction Case
• DOJ Probing Disney-FuboTV Deal, And Other Rumors
• 10 Arbitrations And A 5th Circ. Ruling Flag Arb. Clause Risks
• Polsinelli Gains 2 Healthcare Shareholders In Denver
• Harvard Seeks To Move 'Swiftly' In $2B Fund Freeze Suit
• Keys To Handling Digital Investigations In Pharma IP Litigation
• UPS Paying $1.6B For Andlauer's Healthcare Logistics Co.
• Latham-Led LLR Clinches 7th Fund With $2.45B Committed
• 11th Circ. Considers Timeliness Of J&J Pelvic Mesh Claims
• FDA Warns Of Health Risks In Topical Hair Loss Drug
• Curaleaf Sues Ex-VP For Alleged Breach Of Noncompete
• Fed. Circ. Agrees MS Generic Drug Didn't Infringe Metacel IP
• Ex-Sprinter Turned Track Coach Cops To Olympic Doping Rap
• Law Firm Fights Sanctions Bid In Mootness Fee Row
• Ex-Exec Says Centene Harassed Him Over Void Noncompete
• Judge Lifts Biocon Eye Med Biosimilar Ban After Settlement
• Sandoz, Novartis Cut Price-Fixing Deal With South Carolina
• Genetic Testing Co., Marketer Settle FCA Case For $6M
• FCA Suit Over Allergan's Alleged Kickbacks Trimmed
• Eli Lilly Sues 4 Telehealth Cos. For Weight Loss Drug Copies
• M&A 'Pause' Requires Nimble, Creative Dealmaking
• Power To The Paralegals: The Value Of Unified State Licensing
• Swiss Drug Developer Veraxa To List In US In $1.6B SPAC Deal
• Apple Should Prevail In Heartbeat Patent Suit, Judge Says
• BlackRock Funds Drop Claims In Valeant Stock Suit
• Pharmaceutical Co. Buyers Win Del. Fraud Suit Revival
• 23andMe Has Received 'Significant Interest' In Ch. 11 Auction
• Jury Issues Mixed Verdict In Surgeon's NuVasive Patent Fight
• What's Next For Lab Test Regulation Without FDA Authority
• J&J Ends Trade Secrets Suit Against Now Deceased Ex-Exec
• Hogan Lovells Adds Ex-HHS Atty To Health Practice
• Nuclear Startup To Go Public Through $475M SPAC Deal
• MoFo Adds Perkins Coie FDA Regulatory Leader In DC
• Pain Management Co. Says Customers Pilfered Product Ideas
• Kentuckian Sues Medtronic, FDA Over Spinal Cord Stimulator
• Sun Pharma Accuses Drugstores Of $10M Refund Scheme
• Imprisoned Ex-Pharma Exec Must Pay SEC $1.8M
• Harvard Sues Trump Admin Over $2B Funding Freeze
• 10 Soft Skills Every GC Should Master
• GenapSys Fights Paul Hastings Bid To Ax Malpractice Suit
• Ozempic Maker, Texas Pharmacy Settle Knockoff Drug Claims
• Neogen Selling Cleaners Biz To Kersia For $130M
• 6 Criteria Can Help Assess Executive Branch Actions
• Justices Mull 5th Circ. Redo In ACA Preventive Care Fight
• Justices Kick Flavored-Vape Dispute Back To 5th Circ.
• Walgreens To Pay DOJ $300M Over Invalid Prescriptions
• $6.5M Deal In Amazon's PillPack TCPA Suit Gets Final OK
• Biotech Execs Seek Ch. 15 Pause Pending Trustee Removal
• Lilly Blasts Compounders' 'Scattershot' Bid To Reverse FDA
• PBMs Press 8th Circ. Bid To Pause FTC Case
• Ill. Justices To Weigh Scope Of Standard Pollution Exclusions
• An Unrestrained, Bright-Eyed View Of Legal AI's Future
• Federal Cannabis Law Reform Eyed In Bipartisan Push
• Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal
• DC Circ. Has No Sympathy For Novartis Over Generic Entresto
• Solicitor General's Office Now Features Two Top Lieutenants
• Bard Plant's Emission Controls Weren't Up To Snuff, Jury Told
• Ozempic Caused Blindness, NC Woman Claims
• RI Judge Wants To Know Who's Behind $11B Health Grant Cuts
• Nestle Can't Nix Diabetics' Boost Glucose False Ad Suit
• Patent Office Plans Rulemaking For New PTAB Denial Process
• Tracking The Evolution In Litigation Finance
• Firms Seek Fee Relief Over 'Grossly Unfair' Seresto MDL Snub
• AstraZeneca Unit Hit With Antitrust Suit Over Soliris
• Keys To Regulatory Diligence In Life Sciences Transactions
• 9th Circ. Revives Defect Suit Against CR Bard Over Clot Filter
• How Courts Weigh Section 1782 Discovery For UPC Cases
• 3rd Circ. Questions Walmart's Duty To Disclose Opioid Probe
• In Vape Case, Justices Must Focus On Agencies' Results
• Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge
• Cooley Boosts Life Sciences Team With Latham Partner Hire
• Calif. Court Says Co.'s Heart Monitors Are Not Tax-Exempt
• Moderna Says New Drug Plant Riddled With Defects, Mold
• UK Litigation Roundup: Here's What You Missed In London
• Haynes Boone Atty Joins Mintz Capital Markets Team
• Volunteer Firefighting Makes Me A Better Lawyer
• 11th Circ. Revives FCA Claim Against Fla. Medical Suppliers
• Bard Sickened Ga. Man With Medical Gas Pollution, Jury Told
• Geron Shareholder Sues Execs Over Drug Launch Claims
• Wyo. Justices Skeptical Of State Abortion Bans' Legality
• Sterlington Adds Ex-Loeb & Loeb PTAB Trials Head In Calif.
• Biotech Glycomine Closes $115M Series C Funding Round
• California Challenges Trump's Economic Emergency Tariffs
• Astellas Bladder Drug Patent Survives Following Bench Trial
• Biogen, Genentech Head To June Trial Over MS Drug Royalties
• Novo Nordisk Seeks Toss Of Hospital's Insulin Pen Suit
• Fed. Circ. Won't Revive Stryker Unit's Antiseptic Patents
• 39 AGs Urge Congress To Ban PBM Pharmacy Ownership
• Ga. Woman Says Baby 'Ripped Away' After Embryo Mix-Up
• Research Co. Inks $7.15M Deal To End Stock Plan Suit
• Haleon Paying $221M For Full Control Of Chinese Pharma JV
• Kirkland-Led Linden Wraps $5.4B Healthcare-Focused Fund
• E-Discovery Quarterly: The Perils Of Digital Data Protocols
• Musk Supports Deleting IP Law, Attorneys Say Let's Not
• Fed. Circ. Hears Teva Challenge To J&J Schizophrenia Drug
• Juul Seeks Ax of Noncompliant Plaintiffs In E-Cig Suits
• Ozempic Pretender On Sale In Conn., Novo Nordisk Says
• J&J Units Beat Patent Suit Over Surgical Screw Designs
• Women's Healthtech Co. Chiaro Files Ch. 15 In Delaware
• Defense Strategies After Justices' Personal Injury RICO Ruling
• Takeda Gets Actos Case Paused For Class Cert. Review
• Sandoz Sues Amgen Over Enbrel Biosimilar
• 3 Ex-Cooley IP Attys Help Launch New Fenwick Boston Office
• Law School's Missed Lessons: Preparing For Corporate Work
• Amgen Can't Ditch Regeneron's Bundling Antitrust Suit
• Express Scripts Judge Asks If Khan's FTC Exit Affects Suit
• Dentsply Brass Face Investor Suit Over Alleged Dental Injuries
• Tariff Reprieve Offers Little Comfort For Venture-Backed IPOs
• Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement
• Telehealth Co. Sued Over 2024 Data Breach
• AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics
• Philly Dispensary's $24.5M Award Upheld In Fraud Suit
• 7th Circ. Asks For Ill. Justices' Input On Pollution Exclusion
• 5th Circ. Revives Unfair Competition Fight Over Arthritis Drug
• Future Pak Goes Public With $255M Theratechnologies Bid
• UK Litigation Roundup: Here's What You Missed In London
• AbbVie Wants ND, SD Drug Pricing Laws Blocked
• Ga. Rehab Facility Settles In $77.6M Wrongful Death Suit
• IP Forecast: Novartis' Entresto Fight Heads To DC Circ.
• Vanda Sues FDA To Block Off-Label Use Drug Promo Regs
• 9th Circ. Open To Sending Invisalign Antitrust Suit To Trial
• Pharma Giants Sued Over Ex-Sanofi Drug Delivery Patents
• ITC Blocks Imports Of Copycats Of Eli Lilly Weight Loss Drug
• Pa. Family Blames Fatal House Fire On Prosthetic Arm Battery
• Pharma Cos.' Patent Practices Limit Drug Access, Report Says
• 3 Red Flags To Watch For When Valuing Patent Portfolios
• Holmes Seeks Full 9th Circ. Review Of Theranos Fraud Appeal
• 3rd Circ. Backs Hospital In Doctor's COVID Vaccine Bias Suit
• How Cos. Can Mitigate Increasing Microplastics Liability Risk
• A Cold War-Era History Lesson On Due Process
• Purdue Cleared To Start Ch. 11 Claims Processing Early
• Kroger Customers Get Certification In Prescription Billing Suit
• Improv Makes Me A Better Lawyer
• Device Co. Suggested 'Crazy Glue' To Fix Fatal Flaw, Suit Says
• Tillis Says China IP Theft Should Be Priority In Trade Talks
• 'You Won,' Fed. Circ. Judge Tells Drug Co. Fighting Injunction
• Mich. Panel: Gilead Immune From Recalled COVID Drug Suit
• Full Fed. Circ. Lets Stand Patent Tied To $400M Labcorp Loss
• 9th Circ. Won't Restore Competing TM Claims In Vitamin Row
• Bristol Myers Beats Pomalyst Antitrust Suit Alleging IP Fraud
• Ga. Hospital Faces Suit Over Toddler's Death From Ant Bites
• FDA: Pharmacies' Bid To Keep Making Eli Lilly Drug Is 'Absurd'
• 2nd Circ. Allows Takeda To Appeal Actos Antitrust Class Cert.
• White & Case-Led EQT Inks Nearly $3B Health Deal With KKR
• How BigLaw Executive Orders May Affect Smaller Firms
• FDA Slow To Act On Hemp And Vapes, Congress Hears
• Ex-Client Wants $1M Cut From McCarter & English Fee Win
• Religious Mission Justifies Philly Injection Site, 3rd Circ. Told
• New Mexico 3rd State To Legalize Psilocybin Therapy
• Pillsbury Expands Houston Office With 3 Corporate Attys
• Lawsuits Shouldn't Be Shadow Assets For Foreign Capital
• Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight
• Expert And 'Worthlessness Theory' Ejected In Valsartan MDL
• Medicare Drug Price Plan Tramples Constitution, 3rd Circ. Told
• Fed. Circ. Considers Sandoz's Bid To Undo $39M Patent Loss
• Pacira Reaches IP Deal Allowing Generic Painkiller In 2030
• Judge Preserves Psilocybin Trade Secrets Theft Suit
• How To Accelerate Your Post-Attorney Career Transition
• 5 Key Licensing Considerations For AI Innovations
• Fed. Circ. Affirms Alkem's Generic Antibiotic Not Barred By IP
• Bernstein Litowitz, Kessler Topaz Seek To Lead GSK Investors
• Longtime Cooley Life Sciences Ace Jumps To Wilson Sonsini
• Ruling Adds To Risk Of Patent Format Tied To Improvements
• Torrent Seeks Arbitration In Drug Commercialization Fight
• Policy Group Tells 4th Circ. Drug Discount Law Needs Reform
• Birth Control Companies Escape Conn. Long-Arm Injury Suits
• Drug Buyers, Generics Cos. Fight Over Bellwether Litigation
• Incyte Can't Get Pretrial Win In Novartis Royalty Fight
• A Higher Bar For Expert Witnesses In Drug Patent Litigation
• AGs Announce $335M Opioid Deal With Mylan
• Monthly Merger Review Snapshot
• Compensation Up For Quest Diagnostics GC After Earlier Dip
• Law School's Missed Lessons: Be An Indispensable Associate
• AbbVie Says Aurobindo's Rinvoq Generic Infringes Patent
• Fed. Circ. Backs Ruling Against Parents In Vaccine Case
• NIH Wants Prompt 1st Circ. Review Of Agency's Grant Caps
• Azzur Creditors Call $61M DIP Rollup Excessive
• Radius Health Stockholders Sue Ex-CEO After $890M Co. Sale
• 2nd Circ. Won't Revisit Benefit Math In Colgate ERISA Suit
• Mich. Justices Order More Arguments In Lilly Insulin Case
• Masimo Shareholder Vote Suit Against Founder Moved To Calif.
• GSK Inks $67M Deal To Resolve Zantac Cancer Risk FCA Suit
• FTC Chair Seeks to Revive Insulin Case By Ending Recusal
• Taxation With Representation: Ropes & Gray, Paul Hastings
• Birding Makes Me A Better Lawyer
• AGs Sue To Halt Disruptions To NIH Grant Funding
• Optum, Express Scripts Want Judge Ousted From Opioid MDL
• GSK, Pfizer Agree To End Patent Fight Over RSV Vaccines
• International Disputes And Trade Lawyer Heads To Foley Hoag
• AI Dominated Venture Funding In Q1 As Broader Market Lags
• Compounders Say Shortage Of Weight Loss Drug Continues
• Senate Panel Advances Bills Tackling Drug Patents, Pricing
• 2nd Circ. Judge Thinks Drug Price Fight Sounds Like Antitrust
• Nestlé, Other Parent Cos. Freed From Baby Food Metals MDL
• Amazon, Biotech Net $1.9M Win Against Fake Supplement Sellers
• Texas Appeals Court Backs UT Royalty Award In Pet Co. Suit
• RI Judge Hits Pause On Billions In Health Grant Funding Cuts
• Justices' Ruling Empowers FDA To Rein In Vapes, Experts Say
• $10M Heritage Pharma Price-Fixing Deal Gets Final OK
• 5 Fed. Circ. Clashes To Watch This Month
• NIH Sued By Researchers Over 'Ideological Purge' On Grants
• With Dems Fired, GOP Recused, FTC Pauses PBMs Case
• PE Firm TPG Wants Endo Trust's Transfer Suit Tossed
• Zoll Gets Parts Of Data Breach Class Action Tossed
• MSN Denied More Relief For 'Falling Sky' In Entresto Dispute
• Garmin Beats Fitness Tracker Patent Suit, For Now
• CVS Asserts DOJ's Opioid Prescription Suit Lacks Facts
• Bidi Vapor Says FDA Denial Of E-Cig Was Unlawful
• Orthodontic Software Co. Hit With Data Breach Class Action
• Adapting To Private Practice: From DOJ Leadership To BigLaw
• Justices Broaden RICO Reach To Personal Injuries
• Supreme Court Backs FDA Block Of Flavored Vapes
• FDA Beats Challenge To Approval Of Elanco's Cattle Gas Drug
• Takeda Antitrust Trial Over Actos Generics Set For July
• Fla. Defends Sandoz Price-Fixing Settlement Terms
• Two More Pharmacies Hit With Eli Lilly Weight Loss Drug Suits
• No Inequitable Conduct From Fresenius Foe, Judge Says
• Fed. Circ. Ruling Reaffirms Listing Elements Separately Is Key
• Ex-Biotech CEO Wrongly Sentenced To 7 Years, DC Circ. Told
• IBM And J&J Beat 'Speculative' Data Breach Suit, For Now
• Talc Claimants Tell 3rd Circ. Whittaker Couldn't File Ch. 11
• FDA Cuts Prompt Biotech Players To Rethink Deal Strategies
• State Extended Producer Responsibility Laws: Tips For Cos.
• Law Firm Executive Orders Create A Legal Ethics Minefield